Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

The safety of repeated ketamine therapy, particularly for long-term use, requires further investigation. Esketamine, the S-enantiomer of ketamine, was approved by the FDA in 2019 for the treatment ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.